What GLP-1 receptor agonists actually are

GLP-1 receptor agonists are the most consequential class of metabolic medications introduced in the last 30 years. They started as type 2 diabetes therapies in the 2000s and have evolved into the first widely-effective pharmacological treatment for obesity. As of 2026, the class includes four FDA-approved molecules in active clinical use (semaglutide, tirzepatide, liraglutide, dulaglutide), one approval-pending oral candidate (orforglipron), and one Phase 3 triple-agonist (retatrutide) that may surpass everything currently on the market.

This cornerstone is the editorial hub for the Weight Loss pillar. It anchors the tapering off GLP-1s without rebound, GLP-1 muscle preservation, Orforglipron deep dive, Rybelsus vs Orforglipron, GLP-1 compounding cliff cornerstone, and the MAHA framework explainer.

Evidence tier: 1 — direct citation of Phase 3 RCT results (STEP, SURMOUNT, SURPASS, PIONEER, ATTAIN, TRIUMPH trial programs) and FDA approval documentation.

The mechanism — what GLP-1s actually do in the body

Evidence tier: 2 — well-characterized GLP-1 receptor pharmacology.

GLP-1 (glucagon-like peptide-1) is a natural gut hormone released after eating. It does several things simultaneously:

Stimulates insulin release from pancreatic beta cells in a glucose-dependent way (only when blood sugar is elevated, reducing hypoglycemia risk vs older diabetes drugs).

Suppresses glucagon secretion from pancreatic alpha cells, reducing hepatic glucose output.

Slows gastric emptying — food stays in the stomach longer, producing prolonged fullness.

Acts on hypothalamic appetite centers to reduce hunger and food cravings, including reducing the rewarding properties of high-calorie food.

Modulates energy expenditure modestly.

The natural hormone has a half-life of 1-2 minutes — degraded by DPP-4 enzyme. Pharmaceutical GLP-1 receptor agonists are modified to resist DPP-4 degradation, extending half-life to days. This converts a postprandial signal into a sustained pharmacological intervention.

The clinical effect on weight loss comes mainly from the reduced hunger + earlier satiety + reduced food rewards. Patients eat less because eating less feels natural rather than forced. This is qualitatively different from older weight-loss drugs (phentermine, orlistat) that worked by stimulant effect or fat malabsorption.

The current FDA-approved options

Evidence tier: 1 — FDA approval documentation, current as of May 2026.

Five FDA-approved GLP-1 (or GLP-1-adjacent) products in active clinical use:

Wegovy (semaglutide) — Novo Nordisk - Mechanism: GLP-1 receptor agonist - Indications: obesity (BMI ≥30, or ≥27 with comorbidities), cardiovascular risk reduction (SELECT 2023), pediatric obesity (≥12 years) - Dose: 0.25 → 2.4 mg/week SC, titrate over 16 weeks - Mean weight loss (STEP-1, 68 weeks): 14.9% TBWL - US list price: ~$1,350/month

Ozempic (semaglutide) — same molecule, T2D indication - Lower-dose version of the Wegovy molecule, originally approved 2017 for T2D - Cardiovascular outcomes data (SUSTAIN-6, SOUL pending) - Off-label for weight loss (most prescriptions outside the approved indication) - US list price: ~$970/month

Rybelsus (oral semaglutide) — Novo Nordisk - Same semaglutide molecule, oral tablet with SNAC absorption enhancer - ~1% bioavailability vs ~80% injectable - Approved 2019 for T2D, obesity indication pending PIONEER-PLUS - Real-world weight loss: 4-8% at standard 7-14mg dose, ~17% at 50mg in PIONEER-PLUS - Strict fasting + water protocol required

Zepbound (tirzepatide) — Eli Lilly - Mechanism: dual GLP-1 + GIP receptor agonist (more potent than GLP-1 alone) - Indications: obesity, OSA in obese adults (Dec 2024) - Dose: 2.5 → 15 mg/week SC, titrate over 16-24 weeks - Mean weight loss (SURMOUNT-1, 72 weeks): 20.9% TBWL at 15mg - Beat semaglutide head-to-head in SURMOUNT-5 (20.2% vs 13.7%) - US list price: ~$1,060/month

Mounjaro (tirzepatide) — same molecule, T2D indication - Approved 2022 for T2D - US list price: ~$1,050/month

Saxenda (liraglutide) — Novo Nordisk - Older daily-injection GLP-1, approved 2014 for obesity - Mean weight loss: 8% TBWL at 56 weeks - Largely superseded by weekly options - US list price: ~$1,350/month

Pipeline molecules near approval

Evidence tier: 2 — Phase 3 published data, FDA filing status as of May 2026.

Orforglipron (Eli Lilly) — small-molecule oral GLP-1 receptor agonist - Not a peptide — chemically distinct from semaglutide - Phase 3 ATTAIN-1: ~14.5% TBWL at 36mg over 72 weeks - No fasting requirement (unlike Rybelsus) - NDA filing expected H2 2026 - Likely launch 2027 - Estimated launch price: $700-1,200/month

Retatrutide (Eli Lilly) — triple agonist (GLP-1 + GIP + glucagon) - Phase 3 TRIUMPH-1 ongoing, interim data shows ~24% mean TBWL at 48-72 weeks - The glucagon component drives additional energy expenditure, potentially preventing the metabolic slowdown seen with GLP-1 monotherapy - FDA filing expected H2 2026 or later - Likely 2027-2028 launch - Will be the most-potent weight-loss molecule in the class if approved at trial-level efficacy

CagriSema (Novo Nordisk) — semaglutide + cagrilintide combination - Phase 3 ongoing - Cagrilintide is an amylin analog that complements GLP-1 mechanism - Mean weight loss in earlier studies: ~22% at maintenance dose - Likely 2027 approval pathway

MariTide (Amgen) — GLP-1/GIP receptor agonist with extended half-life - Phase 3 advancing - Monthly dosing potential (vs weekly for current options) - Phase 2: ~16% TBWL at 12 weeks

Weight loss outcomes ranked

Evidence tier: 2 — direct Phase 3 trial comparisons.

Mean total body weight loss at maintenance dose, longest published trial:

| Molecule | Trial | Duration | Mean TBWL | |---|---|---|---| | Retatrutide (12mg) | TRIUMPH-1 | 48-72w | ~24% | | Tirzepatide (15mg) | SURMOUNT-1 | 72w | 20.9% | | Tirzepatide (15mg) | SURMOUNT-5 | 68w | 20.2% | | Semaglutide (50mg oral) | PIONEER-PLUS | 68w | ~17% | | Semaglutide (2.4mg SC) | STEP-1 | 68w | 14.9% | | Semaglutide (2.4mg SC) | SURMOUNT-5 | 68w | 13.7% | | Orforglipron (36mg) | ATTAIN-1 | 72w | ~14.5% | | Liraglutide (3.0mg) | SCALE | 56w | 8.0% |

The tirzepatide-vs-semaglutide head-to-head (SURMOUNT-5) is the most-cited comparison in current practice. Tirzepatide produces ~50% more weight loss than semaglutide at maximum approved doses. Retatrutide, when approved, is positioned to surpass both.

For our depth-comparison content, see Semaglutide vs Tirzepatide, Retatrutide vs Tirzepatide, Oral vs injectable semaglutide, and Rybelsus vs Orforglipron.

Side effects — what's common, what's serious

Evidence tier: 2 — Phase 3 adverse event data + post-marketing surveillance.

GLP-1 side effects fall into three categories: common GI effects (manageable), uncommon serious effects (worth knowing about), and theoretical long-term concerns (incompletely characterized).

Common GI side effects (>10%): - Nausea (33-44% across molecules, often dose-dependent) - Diarrhea (~25%) - Constipation (~17%) - Vomiting (~20%, dose-dependent) - Decreased appetite (the desired effect, sometimes excessive)

These typically improve with time on therapy and slower dose titration. Most patients adapt within 4-8 weeks of starting or after each dose escalation.

Less common but clinically meaningful (~1-5%): - Gallbladder disease and gallstones (cholelithiasis 1.5-2.0%, cholecystitis 0.5-1.0%) - Pancreatitis (rare but reported; risk increased in patients with prior pancreatitis history) - Diabetic retinopathy progression (in T2D patients, possibly related to rapid glycemic improvement) - Hypoglycemia (only when combined with insulin or sulfonylureas; minimal monotherapy risk)

Black-box warning territory: - Medullary thyroid carcinoma (rodent C-cell tumors documented; human relevance debated; class contraindication in MEN2 syndrome and personal/family history of MTC) - Acute pancreatitis (warning, not contraindication)

Theoretical / emerging concerns: - Sarcopenia / accelerated lean mass loss (~25% of total weight loss is lean tissue without intervention) - Bone density loss with extended use (limited data, mechanism plausible) - Suicidal ideation (early signal investigated 2023-2024; FDA found no causal relationship in formal review) - "Ozempic face" — cosmetic gauntness from rapid weight loss - Gastroparesis-related complications (anesthesia risk; APSF now recommends extended NPO time before procedures)

Lean mass preservation — the underrecognized issue

Evidence tier: 3 — emerging body composition data.

A standard concern with GLP-1 therapy: roughly 25% of total weight loss is lean mass (muscle + organ tissue) rather than fat. For a patient losing 25% of body weight on tirzepatide, that's ~6% lean mass loss — clinically meaningful, especially in older adults already at sarcopenia risk.

Three mitigation strategies have evidence support:

Resistance training — the strongest single intervention. 2-3x/week resistance training during GLP-1 therapy substantially reduces lean mass loss in published studies.

Adequate protein intake — 1.6-2.2 g/kg/day during active weight loss preserves lean mass better than standard 0.8-1.0 g/kg recommendations.

Tesamorelin or sermorelin adjunct — GH-axis peptides may support lean mass retention. The evidence is mostly mechanistic + small clinical observational, not RCT-grade. See GLP-1 muscle preservation: Tesamorelin, training, protein for the full protocol.

The "lose weight fast and lose nothing" framing is misleading. Substantial weight loss without lean mass attention produces a thinner-but-weaker phenotype that increases fall risk, metabolic deterioration, and rebound weight regain after discontinuation.

Cardiovascular outcomes — when GLP-1s are more than weight loss

Evidence tier: 1 — Phase 3 cardiovascular outcomes trials.

Several GLP-1s now have FDA-approved cardiovascular outcomes indications based on completed CVOT trials:

Semaglutide (SELECT 2023) — 8,803 adults with obesity + established CV disease, no diabetes. 20% reduction in MACE (major adverse cardiovascular events) at 3 years. This is the trial that converted Wegovy from "obesity drug" to "obesity drug with cardiovascular benefit," opening insurance coverage substantially.

Liraglutide (LEADER 2016) — T2D patients with high CV risk. 13% MACE reduction.

Dulaglutide (REWIND 2019) — T2D patients. 12% MACE reduction.

Semaglutide (SOUL ongoing) — oral semaglutide CVOT, expected 2026-2027 readout.

Tirzepatide (SURPASS-CVOT ongoing) — expected 2027 readout.

The cardiovascular benefit appears to be at least partly independent of the weight loss itself — patients who lose less weight on GLP-1s still see cardiovascular event reduction. This expands the indication population well beyond pure weight-loss use.

Compounded vs branded — the access question

Evidence tier: 2 — FDA regulatory framework + post-shortage market dynamics.

During the 2022-2024 GLP-1 supply shortage, 503B compounding pharmacies stepped in to provide compounded semaglutide and tirzepatide at a fraction of branded pricing. This created a substantial DTC telehealth ecosystem (HIMS, Mochi, Henry Meds, Ro and others) selling compounded GLP-1s at $200-500/month vs $1,000-1,350 branded.

The May 4, 2026 FDA proposed rule excluding semaglutide and tirzepatide from the 503B bulks list materially restricts this pathway. The full implications are covered in the 503B GLP-1 compounding cliff cornerstone. Short version:

503A pharmacies retain a documented-medical-necessity pathway, narrower but legal
503B mass-compounded supply faces phase-out timeline (2026-2027 effective dates likely)
Patients on compounded supply have 6-18 months to plan transition
Branded Wegovy/Zepbound becomes the most regulatory-stable path

Patients currently on compounded GLP-1s should work with their prescriber on transition timing, insurance navigation for branded products, or appropriate taper-to-maintenance protocols.

Tapering off — what happens when you stop

Evidence tier: 2 — STEP-4 trial + extension data.

The STEP-4 trial (Rubino et al, 2021) is the foundational study on what happens after GLP-1 discontinuation. Patients who reached their target weight on semaglutide and then discontinued regained an average of 11.6% TBWL within one year — about two-thirds of the lost weight came back.

This isn't a defect in the drug — it's a feature of how obesity biology operates. GLP-1 therapy doesn't cure the underlying drive toward weight regain; it suppresses it pharmacologically. When the suppression stops, the drive returns.

Three reasonable approaches to discontinuation:

Indefinite maintenance — accept that GLP-1 therapy is a long-term intervention like blood pressure medication or statins. Maintenance dose is typically 50-75% of weight-loss dose. Most patients who maintain weight long-term are on indefinite therapy.

Structured taper — reduce dose gradually over 12-24 weeks while building maintenance behaviors (food tracking, exercise consistency, sleep). Some patients can sustain weight without medication after a structured taper; many regain.

Lower-dose maintenance with intermittent escalation — stay on a low maintenance dose indefinitely with brief escalation periods if weight creeps back up. Not formally studied but increasingly used in practice.

Full taper protocols, cost considerations, and adjunct strategies are covered in tapering off GLP-1s without rebound.

Decision tree — which GLP-1 for whom

Evidence tier: 3 — practitioner reasoning + Phase 3 evidence base.

For most patients in 2026, the decision tree:

T2D patient + cardiovascular risk — semaglutide first-line (SELECT data + SUSTAIN-6 cardiovascular benefit + good T2D control)

Obesity primary, no T2D, no cardiovascular history — tirzepatide for maximum weight loss, semaglutide for cardiovascular benefit

Obesity + obstructive sleep apnea — tirzepatide (only GLP-1 with OSA indication)

T2D primary — tirzepatide for maximum HbA1c reduction, semaglutide for established CV outcomes data

Needle aversion — Rybelsus (oral semaglutide) now, orforglipron (oral small molecule) when approved

Limited budget — generic-pathway considerations (currently none for GLP-1s; expect first generics 2030+)

Pregnancy planning — discontinue GLP-1 ≥2 months before conception

Older adults concerned about sarcopenia — combine any GLP-1 with resistance training + adequate protein + consider tesamorelin adjunct

Cancer history (medullary thyroid carcinoma family) — class contraindication; do not start

History of severe pancreatitis — caution; consider non-GLP-1 alternatives

The lifestyle reality

Evidence tier: 2 — RCT outcomes are achieved with concomitant lifestyle intervention.

GLP-1 trial outcomes are not "drug alone" outcomes. Every Phase 3 trial includes lifestyle intervention (typically dietary counseling + exercise recommendations) as part of the protocol. The drug-only effect would be smaller.

In real-world practice, patients who pair GLP-1 therapy with: - Resistance training 2-3x/week - Protein intake 1.6-2.2 g/kg/day - Adequate sleep (7-9 hours) - Limited alcohol (alcohol amplifies GLP-1 nausea + adds calories) - Active monitoring of muscle mass

...achieve substantially better long-term outcomes than patients who treat GLP-1 as a stand-alone solution.

The "magic weight loss drug" framing in popular media is misleading. GLP-1s make sustained weight loss substantially easier than was possible with prior interventions. They don't make it effortless.

Cost reality

Evidence tier: 4 — observational pricing as of May 2026.

US prices range substantially based on insurance, indication, and source:

| Source | Cost/month | Notes | |---|---|---| | Branded Wegovy (cash) | ~$1,350 | Manufacturer savings card brings to ~$650 | | Branded Wegovy (insured, with PA) | ~$25-100 copay | If covered | | Branded Zepbound (cash) | ~$1,060 | Lower than Wegovy | | Ozempic (T2D coverage) | ~$25-150 copay | Most insured patients | | Compounded semaglutide (DTC) | ~$200-500 | Pre-503B-cliff pricing | | Compounded tirzepatide (DTC) | ~$300-600 | Pre-503B-cliff pricing | | Liraglutide (Saxenda) | ~$1,350 | Mostly superseded |

Insurance coverage has expanded dramatically since: - Wegovy SELECT cardiovascular indication (2023) - Zepbound OSA indication (2024) - Multiple state-level Medicaid coverage decisions

For most US patients with documented BMI ≥30 (or ≥27 with comorbidities), insurance coverage is increasingly attainable through prior authorization. The cash-pay reality is shifting from "expensive but feasible" to "covered for most patients with documented indication."

Long-term considerations

Evidence tier: 3 — emerging long-term safety + outcomes data.

Several questions don't yet have definitive answers:

How long should patients stay on GLP-1s? Probably indefinitely for most. Obesity is a chronic condition; pharmacological suppression of the obesity-related drives requires sustained intervention.

What about pregnancy? Discontinue 2+ months before planned conception; no GLP-1 has pregnancy safety data adequate to support use during conception or pregnancy.

Bone density? Limited data. Long-term users should monitor bone density baseline + every 2-3 years.

Cancer risk? Beyond the rodent C-cell tumor finding, no clear human signal. Long-term surveillance is ongoing.

Sarcopenia in older adults? Clinical concern in adults 65+. Resistance training + protein + monitoring become more important with age.

Generic availability? Semaglutide goes off patent ~2031, tirzepatide ~2036. Generic competition will dramatically lower prices but is years away.

Limitations

This cornerstone covers what's known and prescribed in 2026. Real limits:

Not medical advice. Every patient's GLP-1 candidacy depends on their full medical picture, which only a prescriber can evaluate
Pricing changes frequently. Manufacturer savings programs, insurance formularies, and compounded supply prices all shift
Long-term safety beyond 5-7 years isn't well-characterized for any current GLP-1 — they're newer drugs than the cardiovascular event data suggests
Pregnancy + breastfeeding require specialty consultation
Cancer history considerations require oncology input
The compounded landscape is unstable — May 2026 503B proposal is moving target

What we'll be tracking

Orforglipron NDA filing + FDA review (H2 2026)
Retatrutide TRIUMPH-1 final data + FDA filing
CagriSema Phase 3 readouts
SOUL trial readout (oral semaglutide cardiovascular outcomes)
SURPASS-CVOT readout (tirzepatide cardiovascular outcomes)
503B final rule timing + scope changes
New insurance coverage decisions for obesity indications
Long-term sarcopenia + bone density data
Generic pathway opening as semaglutide approaches patent expiration

For ongoing context, see the Weight Loss pillar, the 503B GLP-1 compounding cliff cornerstone, Are peptides legal in 2026?, and our clinic directory for prescribing telehealth options.

References

Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. PMID 33567185
Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. PMID 35658024
Aronne LJ, Sattar N, Horn DB, et al. 2025. Tirzepatide vs Semaglutide for Weight Loss in Adults with Obesity (SURMOUNT-5). N Engl J Med. PMID 40353578
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT). N Engl J Med. PMID 37952131
Rubino D, Abrahamsson N, Davies M, et al. 2021. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP-4). JAMA. PMID 33755728
Wharton S, Blevins T, Connery L, et al. 2023. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. PMID 37356469
Knop FK, Aroda VR, do Vale RD, et al. 2023. Oral Semaglutide 25 mg and 50 mg in Adults with Type 2 Diabetes (PIONEER PLUS). Lancet. PMID 37356468
Marso SP, Daniels GH, Brown-Frandsen K, et al. 2016. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med. PMID 27295427
Garvey WT, Frias JP, Jastreboff AM, et al. 2023. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. PMID 37385275

GLP-1 weight loss: the complete 2026 guide (Wegovy, Zepbound, Mounjaro, Ozempic, Rybelsus, Orforglipron, Retatrutide)